| 000 | 01847 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517160940.0 | ||
| 264 | 0 | _c20180713 | |
| 008 | 201807s 0 0 eng d | ||
| 022 | _a1502-7708 | ||
| 024 | 7 |
_a10.1080/00365521.2017.1339825 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBilliet, Thomas | |
| 245 | 0 | 0 |
_aEvolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. _h[electronic resource] |
| 260 |
_bScandinavian journal of gastroenterology _cOct 2017 |
||
| 300 |
_a1086-1092 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies _xblood |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 |
_aC-Reactive Protein _xmetabolism |
| 650 | 0 | 4 |
_aCrohn Disease _xblood |
| 650 | 0 | 4 |
_aCytokines _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Agents _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInduction Chemotherapy |
| 650 | 0 | 4 |
_aInfliximab _xblood |
| 650 | 0 | 4 |
_aInterferon-gamma _xblood |
| 650 | 0 | 4 |
_aInterleukin-10 _xblood |
| 650 | 0 | 4 |
_aInterleukin-6 _xblood |
| 650 | 0 | 4 |
_aInterleukin-8 _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSerum Albumin _xmetabolism |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xblood |
| 700 | 1 | _aCleynen, Isabelle | |
| 700 | 1 | _aBallet, Vera | |
| 700 | 1 | _aClaes, Karolien | |
| 700 | 1 | _aPrincen, Fred | |
| 700 | 1 | _aSingh, Sharat | |
| 700 | 1 | _aFerrante, Marc | |
| 700 | 1 | _aVan Assche, Gert | |
| 700 | 1 | _aGils, Ann | |
| 700 | 1 | _aVermeire, Severine | |
| 773 | 0 |
_tScandinavian journal of gastroenterology _gvol. 52 _gno. 10 _gp. 1086-1092 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/00365521.2017.1339825 _zAvailable from publisher's website |
| 999 |
_c27284739 _d27284739 |
||